SPY334.89+2.52 0.76%
DIA277.50+3.08 1.12%
IXIC11,167.51+82.26 0.74%

GlycoMimetics Reports New Preclinical Data Showing Uproleselan With Venetoclax/Hypomethylating Agent In Acute Myeloid Leukemia May Prolong Survival

GlycoMimetics, Inc. (NASDAQ:GLYC) today announced new preclinical data providing the first evidence that an E-selectin targeting strategy with uproleselan may help patients with acute myeloid leukemia (AML) to overcome

 · 

GlycoMimetics, Inc. (NASDAQ:GLYC) today announced new preclinical data providing the first evidence that an E-selectin targeting strategy with uproleselan may help patients with acute myeloid leukemia (AML) to overcome resistance to venetoclax and hypomethylating agent (HMA)-based therapy. The poster (Abstract #AML-337) entitled “Targeting E-selectin with GMI-1271 Overcomes Microenvironment-mediated Resistance to Venetoclax/HMA Therapy,” will be presented September 9 from 6:15-8:15 p.m. CDT on the virtual platform of the virtual meeting of the Society of Hematologic Oncology (SOHO).

The data presented are from an animal model created using tissue derived from a patient who had developed resistance to venetoclax/HMA. In this model, the addition of uproleselan to the treatment regimen demonstrated robust anti-leukemic activity and a statistically significant prolongation of survival. The research strongly supports the opportunity for additional clinical evaluation of the triple combination of uproleselan, venetoclax and HMA in the frontline, unfit AML patient population.

“We know that binding leukemic cells to E-selectin within the bone marrow niche up-regulates pro-survival mechanisms. This preclinical study shows that by blocking this activity with uproleselan, we can enhance the sensitivity to venetoclax/HMAs. This supports using this treatment regimen to potentially improve outcomes in patients whose duration of response is typically very short,” said John Magnani, Ph.D., GlycoMimetics’ Senior Vice-President of Research and Chief Scientific Officer. “We are excited to share this encouraging data and hope that additional clinical evaluation will provide more insight on the potential of this combination-therapy approach.”

Visit the meeting’s website for more information: https://www.soho2020.com/., The virtual meeting will be held September 9-12, 2020.